Expertise in
2
conditions

Dr. Raid M. Aljumaily

Hematology
Ou Health Stephenson Cancer Center-Thoracic Cancer Clinic
800 NE 10th St # 4500, 
Oklahoma City, OK 
Accepting New Patients
Expertise in
2
conditions
Ou Health Stephenson Cancer Center-Thoracic Cancer Clinic
800 NE 10th St # 4500, 
Oklahoma City, OK 

Overview

Raid Aljumaily is a Hematologist practicing medicine in Oklahoma City, Oklahoma.

Dr. Aljumaily is highly rated in 2 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Ampullary Cancer, Metastatic Uveal Melanoma, and Pancreatic Ductal Adenocarcinoma.

He is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 31 clinical trials. Dr. Aljumaily is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MA

Hospital Affiliations

Mercy Hospital Oklahoma City, Inc
O U Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Ou Health Stephenson Cancer Center-Thoracic Cancer Clinic
800 NE 10th St # 4500, Oklahoma City, OK 73104

Additional Areas of Focus

Dr. Aljumaily has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Other, Procedure, Biological, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nab-paclitaxel, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed
Study Phase: Phase 2/Phase 3
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 2
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: Elimusertib, Irinotecan Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 1
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
View 9 Less Clinical Trials

36 Total Publications

Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 15, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.4 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sami Ibrahimi is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Ibrahimi is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ibrahimi is currently accepting new patients.

Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Expertise in
44
conditions
Dr. Todd M. Kliewer
Hematology | Oncology
Referral may be required

SSM Health Cancer Care

1000 N. Lee Ave., 
Oklahoma City, OK 
 (1.1 miles away)
405-228-7100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Board certified in medical oncology, Todd Kliewer, MD is a physician in the Frank C. Love Cancer Institute at SSM Health St. Anthony Hospital - Oklahoma City and SSM Health Cancer Care in Midwest City. He treats patients in two convenient locations in Midtown Oklahoma City and Midwest City. Dr. Kliewer is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Breast Cancer. Dr. Kliewer is board certified in Oklahoma State Board Of Medical Licensure & Supervision, American Board Of Internal Medicine/Medical Oncology , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . Dr. Kliewer is currently accepting new patients.

Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Expertise in
32
conditions
Dr. Adam S. Asch
Hematology
Referral may be required

Ou Health Stephenson Cancer Center-Transplant & Cellular Therapy Clinic

800 NE 10th St, 
Oklahoma City, OK 
 (0.4 miles away)
405-271-8299
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Adam Asch is a Hematologist practicing medicine in Oklahoma City, Oklahoma. Dr. Asch is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Asch is currently accepting new patients.

Frequently Asked Questions about Dr. Raid M. Aljumaily

How do I make an appointment with Dr. Raid M. Aljumaily?

You can book an appointment with Dr. Raid M. Aljumaily by calling their office at 405-271-1632. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Raid M. Aljumaily a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Raid M. Aljumaily is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Raid M. Aljumaily specialize in?

While Dr. Raid M. Aljumaily is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Ampullary Cancer, and Metastatic Uveal Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Raid M. Aljumaily participate in research or clinical trials?

Yes. Dr. Raid M. Aljumaily has published 36 articles and abstracts on conditions like ALK-Positive Non-Small Cell Lung Cancer. You can view a list of Dr. Raid M. Aljumaily's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Raid M. Aljumaily accept my insurance?

Dr. Raid M. Aljumaily accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 405-271-1632 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aljumaily's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile